CAPRELSA presents various risks, including QT prolongation, severe skin reactions, and lung disease.

Warnings and Special Considerations

Patients should be monitored regularly for signs of QT prolongation, particularly those with electrolyte imbalances. Severe skin reactions like toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome require immediate cessation of the drug. Interstitial lung disease (ILD) and other severe reactions like ischemic cerebrovascular events and heart failure necessitate discontinuation in affected patients.